Patents by Inventor Graham Belfield

Graham Belfield has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20100021953
    Abstract: The present invention relates to an assay method for identifying an agent that modulates arginine transport in a chondrocyte comprising the steps of: (a) identifying an agent that modulates the activity and/or expression of CAT-2; and (b) measuring arginine transport in the chondrocyte in the presence or absence of said agent, wherein a difference between: (a) arginine transport in the absence of the agent; and (b) arginine transport in the presence of the agent is indicative that the agent can modulate arginine transport in a chondrocyte. Therapeutic agents that modulate the expression or activity of CAT-2B could be beneficial for the treatment of inflammatory diseases, particularly osteoarthritis. For example, a CAT-2B antagonist may be useful for the treatment of osteoarthritis.
    Type: Application
    Filed: July 31, 2006
    Publication date: January 28, 2010
    Applicant: ASTRAZENECA AB
    Inventors: Graham Belfield, Stephen Delaney, Philip Rawlins
  • Publication number: 20060211118
    Abstract: The invention provides novel yeast promoters useful for controlling the expression of homologous and heterologous nucleic acid molecules in yeast cells. The yeast promoters are induced by a fermentable carbon source, such as glucose, or a non-fermentable carbon source, such as ethanol, or both. Therefore, expression of nucleic acid molecules encoding a polypeptide under the control of the novel yeast promoters may be regulated by varying the level of a fermentable carbon source, or a non-fermentable carbon source, or both.
    Type: Application
    Filed: May 9, 2006
    Publication date: September 21, 2006
    Applicant: AstraZeneca AB
    Inventors: Graham Belfield, Caroline Oakley
  • Publication number: 20060057676
    Abstract: The invention provides novel yeast promoters useful for controlling the expression of homologous and heterologous nucleic acid molecules in yeast cells. The yeast promoters are induced by a fermentable carbon source, such as glucose, or a non-fermentable carbon source, such as ethanol, or both. Therefore, expression of nucleic acid molecules encoding a polypeptide under the control of the novel yeast promoters may be regulated by varying the level of a fermentable carbon source, or a non-fermentable carbon source, or both.
    Type: Application
    Filed: September 30, 2005
    Publication date: March 16, 2006
    Applicant: AstraZeneca AB
    Inventors: Graham Belfield, Caroline Oakley